67 assets in B-Cell Chronic Lymphocytic Leukemia

Therapeutic assets addressing B-Cell Chronic Lymphocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bms-986403 B-Cell Chronic Lymphocytic Leukemia	Bristol-Myers Squibb	P1	CC (41)
Egfrt/19-28Z/Il-12 Car T-Lymphocytes B-Cell Chronic Lymphocytic Leukemia	Roswell Park Cancer Institute	P1	CC (41)
Jnj-54179060 B-Cell Chronic Lymphocytic Leukemia	Janssen Research & Development, LLC	P1	CC (41)
Jnj-64619178 B-Cell Chronic Lymphocytic Leukemia	Janssen Research & Development, LLC	P1	CC (41)
Jnj-70218902 B-Cell Chronic Lymphocytic Leukemia	Janssen Research & Development, LLC	P1	CC (41)
Jnj-74856665 B-Cell Chronic Lymphocytic Leukemia	Janssen Research & Development, LLC	P1	CC (41)
Jnj-80948543 B-Cell Chronic Lymphocytic Leukemia	Janssen Research & Development, LLC	P1	CC (41)
Jnj-87801493 B-Cell Chronic Lymphocytic Leukemia	Janssen Research & Development, LLC	P1	CC (41)
Loxo-338 B-Cell Chronic Lymphocytic Leukemia	Eli Lilly and Company	P1	CC (41)
Ono-7018 B-Cell Chronic Lymphocytic Leukemia	Ono Pharmaceutical Co., Ltd.	P1	CC (41)
Pevonedistat B-Cell Chronic Lymphocytic Leukemia	City of Hope Medical Center	P1	CC (41)
q702 B-Cell Chronic Lymphocytic Leukemia	Mayo Clinic	P1	CC (41)
Umbralisib B-Cell Chronic Lymphocytic Leukemia	Weill Medical College of Cornell University	P2	CC (40)
Selenious Yeast B-Cell Chronic Lymphocytic Leukemia	Shanghai Zhongshan Hospital	N/A	NR ()

Showing 51 to 67 of 67 assets

PreviousPage 2 of 2Next